A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour
continuous infusion of conivaptan in subjects with severe liver impairment compared to
subjects with normal liver function.